Asia Pacific Central Nervous System Therapeutic Market Size & Outlook

The central nervous system therapeutic market in Asia Pacific is expected to reach a projected revenue of US$ 60,215.3 million by 2033. A compound annual growth rate of 10.1% is expected of Asia Pacific central nervous system therapeutic market from 2026 to 2033.
Revenue, 2025 (US$M)
$28,349.4
Forecast, 2033 (US$M)
$60,215.3
CAGR, 2026 - 2033
10.1%
Report Coverage
Asia Pacific

To keep accessing Horizon, please sign in or register for a free account

  • Access to global market statistics
  • Access to company profiles
  • Free use-cases & research insights

No credit card required*

Asia Pacific central nervous system therapeutic market, 2021-2033 (US$M)

To keep accessing Horizon, please sign in or register for a free account

  • Access to global market statistics
  • Access to company profiles
  • Free use-cases & research insights

No credit card required*

Related Markets

Asia Pacific central nervous system therapeutic market highlights

  • The Asia Pacific central nervous system therapeutic market generated a revenue of USD 28,349.4 million in 2025.
  • The market is expected to grow at a CAGR of 10.1% from 2026 to 2033.
  • In terms of segment, neurodegenerative diseases was the largest revenue generating disease in 2025.
  • Neurodegenerative Diseases is the most lucrative disease segment registering the fastest growth during the forecast period.
  • Country-wise, India is expected to register the highest CAGR from 2026 to 2033.


Asia Pacific data book summary

Market revenue in 2025USD 28,349.4 million
Market revenue in 2033USD 60,215.3 million
Growth rate10.1% (CAGR from 2026 to 2033)
Largest segmentNeurodegenerative diseases
Fastest growing segmentNeurodegenerative Diseases
Historical data covered2021 - 2024
Base year for estimation2025
Forecast period covered2026 - 2033
Quantitative unitsRevenue in USD million
Market segmentationNeurovascular Diseases, CNS Trauma, Mental Health, Neurodegenerative Diseases, Infectious Diseases, CNS Cancer
Key market players worldwideBiogen Inc, Otsuka Pharmaceutical, Eli Lilly and Co, Merck & Co Inc, AstraZeneca PLC, Novartis AG ADR, Teva Pharmaceutical Industries Ltd, Johnson & Johnson, Pfizer Inc


Other key industry trends

  • In terms of revenue, Asia Pacific region accounted for 20.5% of the global central nervous system therapeutic market in 2025.
  • Globally, North America is projected to lead the regional market in terms of revenue in 2033.
  • Asia Pacific is the fastest growing regional market and is projected to reach USD 60,215.3 million by 2033.

No credit card required*

Horizon in a snapshot

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more

Central Nervous System Therapeutic Market Companies

Name Profile # Employees HQ Website
Biogen Inc View profile 7570 225 Binney Street, Cambridge, MA, United States, 02142 https://www.biogen.com
AstraZeneca PLC View profile 89900 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, United Kingdom, CB2 0AA https://www.astrazeneca.com
Otsuka Pharmaceutical View profile 251-500 Tokyo, Tokyo, Japan, Asia https://www.otsuka.co.jp/en/
Eli Lilly and Co View profile 43000 Lilly Corporate Center, Indianapolis, IN, United States, 46285 https://www.lilly.com
Merck & Co Inc View profile 72000 126 East Lincoln Avenue, Rahway, NJ, United States, 07065 https://www.merck.com
Pfizer Inc View profile 88000 66 Hudson Boulevard East, New York, NY, United States, 10001-2192 https://www.pfizer.com
Teva Pharmaceutical Industries Ltd View profile 37851 124 Dvora HaNevi’a Street, Tel Aviv, Israel, 6944020 https://www.tevapharm.com
Novartis AG ADR View profile 76057 Lichtstrasse 35, Basel, Switzerland, 4056 https://www.novartis.com
Johnson & Johnson View profile 134400 One Johnson and Johnson Plaza, New Brunswick, NJ, United States, 08933 https://www.jnj.com

Asia Pacific central nervous system therapeutic market outlook

The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to central nervous system therapeutic market will help companies and investors design strategic landscapes.


Neurodegenerative diseases was the largest segment with a revenue share of 37.47% in 2025. Horizon Databook has segmented the Asia Pacific central nervous system therapeutic market based on neurovascular diseases, cns trauma, mental health, neurodegenerative diseases, infectious diseases, cns cancer covering the revenue growth of each sub-segment from 2021 to 2033.


Asia Pacific region is expected to grow at the fastest rate over the forecast period. High prevalence of neurodegenerative diseases, increasing awareness regarding mental health, and improving healthcare infrastructure in the region are anticipated to boost regional market growth. 

Developed countries in the Asia Pacific region, such Japan, South Korea, and Australia, have better healthcare policies and established public health policies focused on mental health. Moreover, developing countries in the region are reforming healthcare policies to improve the life of patients living with neurological disorders.

Reasons to subscribe to Asia Pacific central nervous system therapeutic market databook:

  • Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
  • Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
  • Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
  • Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
  • Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.

Target buyers of Asia Pacific central nervous system therapeutic market databook

  • Our clientele includes a mix of central nervous system therapeutic market companies, investment firms, advisory firms & academic institutions.
  • 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
  • Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
  • The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.

Horizon Databook provides a detailed overview of continent-level data and insights on the Asia Pacific central nervous system therapeutic market , including forecasts for subscribers. This continent databook contains high-level insights into Asia Pacific central nervous system therapeutic market from 2021 to 2033, including revenue numbers, major trends, and company profiles.

Partial client list

  • logo

Asia Pacific central nervous system therapeutic market size, by country, 2021-2033 (US$M)

Asia Pacific Central Nervous System Therapeutic Market Outlook Share, 2025 & 2033 (US$M)

Asia Pacific central nervous system therapeutic market size, by country, 2021-2033 (US$M)

Sign up - it's easy, and free!

Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our free plan indefinitely.

Explore all plans

Included in Horizon account

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more
Chat with us
Research Assistance
Online